Unknown

Dataset Information

0

Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases.


ABSTRACT: Chemoradiation is the treatment of choice for locally advanced head and neck squamous cell carcinoma (HNSCC). However, radioresistance, which contributes to local recurrence, remains a significant therapeutic problem. In this study, we characterized SM-164, a small second mitochondria-derived activator of caspase -mimetic compound that promotes degradation of cellular inhibitor of apoptosis-1(cIAP-1; also known as baculoviral IAP repeat-containing protein 2, BIRC2) and releases active caspases from the X-linked inhibitor of apoptosis inhibitory binding as a radiosensitizing agent in HNSCC cells. We found that SM-164 at nanomolar concentrations induced radiosensitization in some HNSCC cell lines in a manner dependent on intrinsic sensitivity to caspase activation and apoptosis induction. Blockage of caspase activation via short interfering RNA knockdown or a pan-caspase inhibitor, z-VAD-fmk, largely abrogated SM-164 radiosensitization. On the other hand, the resistant lines with a high level of Bcl-2 that blocks caspase activation and apoptosis induction became sensitive to radiation on Bcl-2 knockdown. Mechanistic studies revealed that SM-164 radiosensitization in sensitive cells was associated with NF-?B activation and TNF? secretion, followed by activation of caspase-8 and -9, leading to enhanced apoptosis. Finally, SM-164 also radiosensitized human tumor xenograft while causing minimal toxicity. Thus, SM-164 is a potent radiosensitizer via a mechanism involving caspase activation and holds promise for future clinical development as a novel class of radiosensitizer for the treatment of a subset of head and neck cancer patients.

SUBMITTER: Yang J 

PROVIDER: S-EPMC3073022 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases.

Yang Jie J   McEachern Donna D   Li Wenyan W   Davis Mary A MA   Li Hua H   Morgan Meredith A MA   Bai Longchuan L   Sebolt Jonathan T JT   Sun Haiying H   Lawrence Theodore S TS   Wang Shaomeng S   Sun Yi Y  

Molecular cancer therapeutics 20110131 4


Chemoradiation is the treatment of choice for locally advanced head and neck squamous cell carcinoma (HNSCC). However, radioresistance, which contributes to local recurrence, remains a significant therapeutic problem. In this study, we characterized SM-164, a small second mitochondria-derived activator of caspase -mimetic compound that promotes degradation of cellular inhibitor of apoptosis-1(cIAP-1; also known as baculoviral IAP repeat-containing protein 2, BIRC2) and releases active caspases f  ...[more]

Similar Datasets

| S-ECPF-GEOD-33827 | biostudies-other
2012-03-01 | E-GEOD-33827 | biostudies-arrayexpress
2012-03-01 | GSE33827 | GEO
| S-EPMC3091962 | biostudies-literature
| S-EPMC2784911 | biostudies-literature
| S-EPMC7714407 | biostudies-literature
| S-EPMC6548673 | biostudies-literature
| S-EPMC5026594 | biostudies-literature
| S-EPMC10410762 | biostudies-literature
| S-EPMC7643013 | biostudies-literature